Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

Outcomes with GLP-1 versus SGLT2 therapies after liver transplantation

Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trial

Metabolism: Clinical and Experimental

Citation & Authors

Metabolism. 2026;185:156790.

Fu-Shun Yen; Pei-Lun Liao; Yao-Min Hung; Chih-Cheng Hsu; Chin-Su Liu; Ming-Chih Hou; Chii-Min Hwu; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

This target trial emulation matched 564 pairs of liver transplant recipients with diabetes. GLP-1 users had lower risks of ischemic heart disease, heart failure, and death than SGLT2 users; the mortality HR was 0.622 (95% CI 0.433–0.894). The association with cirrhosis was only borderline significant and inconsistent across models. Infection, rejection, hepatic failure, and hospitalization did not differ significantly.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗

Key findings

Matching yielded 564 pairs. Compared with SGLT2 inhibitors, GLP-1 receptor agonists were associated with lower risks of heart failure (HR 0.502; 95% CI 0.388–0.650) and all-cause mortality (HR 0.622; 95% CI 0.433–0.894). Graft rejection did not differ significantly.

This study used observational data and cannot establish causality. Findings for cirrhosis risk were not fully consistent across sensitivity analyses and require confirmation in prospective studies.